Domperidone for COVID-19: real-time analysis

Download Image

Post

c19early.org

Domperidone for COVID-19

1 study with 173 patients

No significant improvements are seen in meta-analysis to date.

COVID-19 Domperidone studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−36%

Viral clearance (1)−15%

RCTs (1)−36%

Early (1)−36%

00.511.5+

← Domperidone
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Oct 17 2023	Rabanal Basalo et al., Annals of Medicine, doi:10.1080/07853890.2023.2268535	A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care
Oct 17 2023	36% worse recovery (p=0.23) and 15% worse viral clearance (p=0.62). RCT 173 outpatients with mild-to-moderate COVID-19 showing no significant difference with domperidone versus placebo for viral clearance or symptom recovery.